Literature DB >> 30981007

Durability of Interferon-induced Hepatitis B Surface Antigen Seroclearance.

Yali Wu1, Yali Liu1, Junfeng Lu1, Zhenhuan Cao1, Yi Jin1, Lina Ma1, Nan Geng1, Shan Ren1, Yanhong Zheng1, Chengli Shen2, Xinyue Chen3.   

Abstract

Hepatitis B surface antigen (HBsAg) seroclearance has been recommended as an optimal endpoint of antiviral treatment by the latest chronic hepatitis B management guideline.1 However, few reports investigated the durability of response after HBsAg seroclearance, because of a lower HBsAg seroclearance rate and the difficulty of obtaining a sufficient number of samples for analysis. Our center has made a long-term commitment to investigate the personalized antiviral therapy for chronic hepatitis B. More than 300 patients achieved HBsAg seroclearance by interferon (IFN)-based antiviral treatment. In this study, the durability and the effects of hepatitis B virus (HBV) surface antibody (Anti-HBs) level on relapse after HBsAg seroclearance were investigated.
Copyright © 2020 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Year:  2019        PMID： 30981007     DOI： 10.1016/j.cgh.2019.04.020

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN： 1542-3565            Impact factor:   11.382


  9 in total

1.  Study on the Retreatment, Outcome, and Potential Predictors of Recurrence in Patients With Recurrence of Hepatitis B After Functional Cure.

Authors:  Xiao Lin; Aixin Song; Junfeng Lu; Sujun Zheng; Zhongjie Hu; Lina Ma; Zhenhuan Cao; Hong Li; Yanhong Zheng; Shan Ren; Xinyue Chen
Journal:  Front Immunol       Date:  2022-07-04       Impact factor: 8.786

Review 2.  Functional cure for chronic hepatitis B: accessibility, durability, and prognosis.

Authors:  Aixin Song; Xiao Lin; Xinyue Chen
Journal:  Virol J       Date:  2021-06-03       Impact factor: 4.099

3.  Short-term Peginterferon-Induced High Functional Cure Rate in Inactive Chronic Hepatitis B Virus Carriers With Low Surface Antigen Levels.

Authors:  Qing-Lei Zeng; Zu-Jiang Yu; Jia Shang; Guang-Hua Xu; Chang-Yu Sun; Na Liu; Chun-Xia Li; Jun Lv; Yan-Min Liu; Hong-Xia Liang; Zhi-Qin Li; Ya-Jie Pan; Qiu-Yue Hu; Wei Li; Da-Wei Zhang; Fu-Sheng Wang
Journal:  Open Forum Infect Dis       Date:  2020-06-03       Impact factor: 3.835

4.  Durability of hepatitis B surface antigen seroclearance and subsequent risk for hepatocellular carcinoma: A meta-analysis.

Authors:  Aixin Song; Xiaoxiao Wang; Junfeng Lu; Yi Jin; Lina Ma; Zhongjie Hu; Yanhong Zheng; Chengli Shen; Xinyue Chen
Journal:  J Viral Hepat       Date:  2021-02-08       Impact factor: 3.728

5.  Cost-effectiveness of combination antiviral treatment with extended duration for hepatitis B e antigen (HBeAg)-negative chronic hepatitis B in China.

Authors:  Runqin Li; Xiao Lin; Jing-Yue Wang; Xiaomo Wang; Junfeng Lu; Yali Liu; Zhenhuan Cao; Shan Ren; Lina Ma; Yi Jin; Sujun Zheng; Zhongjie Hu; Li Wang; Xinyue Chen
Journal:  Ann Transl Med       Date:  2021-09

Review 6.  Hepatocellular Carcinoma in Hepatitis B Virus-Infected Patients and the Role of Hepatitis B Surface Antigen (HBsAg).

Authors:  Satinder P Kaur; Arslan Talat; Hamidreza Karimi-Sari; Andrew Grees; Hao Wei Chen; Daryl T Y Lau; Andreea M Catana
Journal:  J Clin Med       Date:  2022-02-21       Impact factor: 4.241

7.  Consolidation treatment needed for sustained HBsAg-negative response induced by interferon-alpha in HBeAg positive chronic hepatitis B patients.

Authors:  Minghui Li; Fangfang Sun; Xiaoyue Bi; Yanjie Lin; Liu Yang; Yao Lu; Lu Zhang; Gang Wan; Wei Yi; Linqing Zhao; Yao Xie
Journal:  Virol Sin       Date:  2022-03-04       Impact factor: 6.947

8.  Durability of Hepatitis B Surface Antigen Loss With Nucleotide Analogue and Peginterferon Therapy in Patients With Chronic Hepatitis B.

Authors:  Anna S Lok; Fabien Zoulim; Geoffrey Dusheiko; Henry L Y Chan; Maria Buti; Marc G Ghany; Anuj Gaggar; Jenny C Yang; George Wu; John F Flaherty; G Mani Subramanian; Stephen Locarnini; Patrick Marcellin
Journal:  Hepatol Commun       Date:  2019-10-10

9.  Chemiluminescent Optical Fiber Immunosensor Combining Surface Modification and Signal Amplification for Ultrasensitive Determination of Hepatitis B Antigen.

Authors:  Xuexue Xu; Rongbin Nie; Jingwen Huang; Li Yang
Journal:  Sensors (Basel)       Date:  2020-08-31       Impact factor: 3.576
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.